Juvenile Dermatomyositis Overview
Learn About Juvenile Dermatomyositis
- Juvenile dermatomyositis
- Amyopathic dermatomyositis
- Juvenile DM
- ADM
- Dermatomyositis sine myositis
Adam Huber is a Pediatric Rheumatologist in Halifax, Canada. Mr. Huber is rated as an Elite expert by MediFind in the treatment of Juvenile Dermatomyositis. His top areas of expertise are Juvenile Dermatomyositis, Dermatomyositis, Juvenile Idiopathic Arthritis (JIA), Arthritis, and Bone Marrow Aspiration.
NIH Clinical Center
Lisa Rider is a Pediatric Rheumatologist in Bethesda, MD. Dr. Rider is rated as an Elite provider by MediFind in the treatment of Juvenile Dermatomyositis. Her top areas of expertise are Juvenile Dermatomyositis, Dermatomyositis, Arthritis, and Juvenile Idiopathic Arthritis (JIA).
Brigitte Meunier-Bader practices in Paris, France. Ms. Meunier-Bader is rated as an Elite expert by MediFind in the treatment of Juvenile Dermatomyositis. Her top areas of expertise are Juvenile Dermatomyositis, Dermatomyositis, Polymyositis, Bone Marrow Aspiration, and Bone Marrow Transplant.
Eligibility: * Patients with known NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, and with other yet undifferentiated autoinflammatory diseases. * Healthy adult and pediatric relatives. * Volunteers
Summary: The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better efficacy than the conventional combination methotrexate (MTX) and corticosteroids over the 24 week study period. Thus, the investigators hypothesize that baricitinib could be ...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center


